Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells

Experimental Oncology

Volumn 26, Issue 4, 2004, Pages 300-306

  Hao, Siguo ^a   Bi, Xuguang ^a   Xu, Shuling ^a   Wei, Yangdou ^b   Wu, Xiaochu ^b   Guo, Xuling ^b   Carlsen, Svein ^a   Xiang, Jim ^a  

^a SASKATCHEWAN CANCER AGENCY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Antitumor immunity; CD40L; Cell fusion; Dendritic cells; Engineered tumor cells

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; DENDRITIC CELL VACCINE; MACROGOL; TUMOR CELL VACCINE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUSION; CELL STRAIN J558; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RESPONSE; HYBRID CELL; MOUSE; MOUSE STRAIN; MYELOMA; MYELOMA CELL; NONHUMAN; PROTECTION; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; ANTIGEN PRESENTATION; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROTECTION; DRUG SYNTHESIS; NATURAL KILLER CELL; TISSUE ENGINEERING;

ANIMALS; ANTIBODY FORMATION; CANCER VACCINES; CD40 LIGAND; DENDRITIC CELLS; GENE THERAPY; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; RATS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 12744278406     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Townsend A, Trowsdale A. The transporters associated with antigen presentation. Semin Cell Biol 1993; 4: 53-61.
2. Yewdell J, Bennink J. Cell biology of antigen processing and presentation to MHC class I molecule restricted T lymphocytes. Adv Immunol 1992; 52: 1-123.
3. Chen L, Ashe S, Brady W, Hellstrom K. Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecule CD28 and CTLA-4. Cell 1992; 71: 1093-102.
4. Chen H, Gabrilovich D, Tampe R, Girgis K, Nadaf S, Carbone D. A functional defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nature Genet 1996; 13: 210-3.
5. Armstrong T, Clements V, Martin B, Ting J, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997; 94; 6886-91.
6. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukine-4, interleukin-7, tumor necrosis factor and interferon gamma. Proc Natl Acad Sci USA 1993; 90: 2774-8.
7. Maric M, Liu Y. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1α-expressing tumor: linkage between inflammation and specific immunity. Cancer Res 1999; 59: 5549-53.
8. Koshita Y, Lu Y, Fujii S, Neda H, Matsuyama T, Satoh Y, Itoh Y, Takahashi M, Kato J, Sakamaki S. Efficiency of TNF-α gene-transduced tumor cells in treatment of established in vivo tumor. Int J Cancer 1995; 63: 130-5.
9. Allione A, Consalvo M, Manni P, Cavallo F, Giovarelli M, Forni G. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL-2, IL-4, IL-6, IL-7, IL-10, TNF, GM-CSF and IFN gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6.
10. Cayeux S, Richter G, Noffz G, Dorken B, Blankenstein T. Influence of gene-modified (IL-7, IL-7 and B7-1) tumor cell vaccines on tumor antigen presentation. J Immunol 1997; 158: 2834-41.
11. Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells. Nat Med 1998; 4: 328-32.
12. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70: 706-15.
13. Asheley D, Faiola B, Nair S, Hale L, Bigner D, Gilbao E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J Exp Med 1997; 186: 1177-82.
14. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
15. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-3.
16. Caux C, Massacrier C, Vanbervliet B. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-72.
17. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-52.
18. + T-helper and a T-killer cell. Nature 1998; 393: 474-8.
19. Soruri A, Fayyazi A, Neumann C, Schlott T, Jung T, Matthes C, Zwirner J, Riggert J, Peters JH. Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dendritic cell/melanoma cell hybridomas. Cancer Immunol Immunother 2001; 50: 307-14.
20. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161: 5516-24.
21. +T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 2000; 101: 316-24.
22. Kugler A, Stuhler G, Waiden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332-6.
23. Caron G, Delneste Y, Roelandts E, Duez C, Bonnefoy JY, Pestel J, Jeannin P. Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J Immnnol 2001; 166: 6000-6.
24. Qi Y, Chen Y, Xiang J. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Interferon Cytokine Res 1996; 16: 771-6.
25. Rosenberg S. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4.
26. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-9.
27. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50: 3-15.
28. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber J, Swetter S, Thompson J, Greenberg P, Roederer M, Davis M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-85.
29. Bucala R, Metz CN. Immunosupressive factors in cancer. In: Cancer immune therapy. Stuhler G, Walden P, eds. Weinheim, Germany: Wiley-VCH 2002; 119-54.
30. Ohnmacht GA, Marincola FM. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J Cell Phisol 2000; 182: 332-8.
31. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161: 5516-24.
32. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
33. Stuhler G, Walden P. Recuitment of helper T cells for induction of tumor rejection by cytolytic T lymphocytes. Cancer Immunol Immunother 1994; 39: 342-5.
34. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994; 263: 518-20.
35. Lespagnard L, Mettens P, Verheyden AM, Tasiaux N, Thielemans K, van Meirvenne S, Geldhof A, De Baetselier P, Urbain J, Leo O, Moser M. Dendritic cells fused with mastocytoma cells elicit therapeutic anti-tumor immunity. Int J Cancer 1998; 76: 250-8.
36. Celluzzi CM, Falo LDJR. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160: 3081-5.
37. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 6279-83.
38. Gong J, Chen D, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-61.
39. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000; 97: 2715-8.
40. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000; 165: 1705-11.
41. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332-6.
42. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T. Antitumor effect of immunization with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 2001; 24: 106-13.
43. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 6279-83.
44. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumor activity against hepaticellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 2001; 36: 764-71.
45. Kugler A, Seseke F, Thelen P, Kallerhoff M, Muller GA, Stuhler G, Muller C, Ringert RH. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol 1998; 82: 487-93.
46. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, Audring H, Guo Y, Sterry W, Walden P. Hybrid cell vaccination for vancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 2000; 85: 618-26.
47. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of phase 1 clinical trial of vaccination of glionma patients with fusion of dendritic and glioma cells. Cancer Immunol Immunother 2001; 50: 337-44.
48. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, Sparbier K, Sterry W, Walden P. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IY patients. Int J Cancer 2004; 110: 730-40.